| Business Summary | | IGEN
International
Inc.
develops
and
markets
products
that
incorporate
the
Company's
proprietary
ORIGEN
technology,
which
permits
the
detection
and
measurement
of
biological
substances.
ORIGEN
is
incorporated
into
instrument
systems
and
related
consumable
reagents.
The
Company
also
offers
assay
development
and
other
services
used
to
perform
analytical
testing.
Products
based
on
the
Company's
ORIGEN
technology
currently
address
the
following
markets:
Life
Science;
Clinical
Testing-In
Vitro;
and
Industrial
Testing. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | IGEN
develops,
manufactures
and
markets
diagnostic
systems
utilizing
its
patented
ORIGEN
technology,
which
is
based
on
electrochemiluminescence.
For
the
three
months
ended
6/01,
revenues
increased
9%
to
$8.3
million.
Net
loss
applicable
to
Common
totalled
$12.3
million,
up
from
$5.7
million.
Revenues
reflect
higher
royalty
income
and
product
sales.
Higher
loss
reflects
an
increase
in
litigation
and
research
and
development
costs. | More
from
Market Guide: Significant
Developments |
| | | | FY2001
Compensation | | Pay | Exer | |
| Samuel Wohlstadter, 59 Chairman,
CEO | $540K | -- | Richard Massey, Ph.D., 55 Pres,
COO, Director | 460K | -- | George Migausky, 46 CFO,
VP, Sec. | 274K | $42K | Dollar amounts are as of 31-Mar-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|